Gram-Scale Synthesis of the C14–C23 Fragment of Eribulin

Eribulin is a structurally simplified and completely synthetic analogue of macrocyclic ketone halichondrin B. In 2010, eribulin was approved by FDA for the treatment of metastatic breast cancer (MBC). Although several research groups have reported the synthetic efforts toward eribulin, it is still a challenge to prepare eribulin in a large scale due to its complex molecular architecture. Herein, we report a novel and efficient route to the C14–C23 fragment of eribulin from cheap l-arabinose.